Today’s generic and biosimilar medicines industry includes a range of diverse companies that have become global leaders both in providing safe and effective FDA-approved medicines and in pioneering new treatment options for patients. Generic competition continues to play a vital role in improving access to pharmaceuticals and driving cost savings to American patients and the health care system.
This growth in the generics and biosimilar industry has led to the creation of thousands of new jobs across the country and to better quality of life for millions of people. But strong headwinds threaten generic and biosimilar competition. Without action to ensure a sustainable, competitive environment for manufacturers of affordable medicines, America’s patients will continue to face increasingly high brand drug prices.
For more details, download White Paper here: